-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In low- and medium-risk populations, there is limited evidence of a link between plasma high levels of triglycerides (TG) and all-cause mortality and atherosclerosis cardiovascular disease (ASCVD) events.
, a study published in JAHA, an authoritative journal in the field of cardiovascular disease, aims to identify whether high levels of TG affect the risk of all-cause death and ASCVD events in population queues.
researchers conducted a retrospective longitudinal queue analysis using three management databases of local health authorities in Italy.
all subjects were tested at least once between 1 January 2010 and 31 December 2015 and followed up until December 2016.
outcome indicators include ASCVD events and all-cause deaths.
researchers compared subjects with normal TG levels (-lt;150 mg/dL) with subjects with TG levels (150-500 mg/dL) and TG very high levels (-gt;500 mg/dL).
the study analyzed 158,042 subjects (142,289 for TG normal, 15,558 for high TG, and 195 for TG).
the overall occurrence and all-cause mortality of ASCVD per 1000 people per year and 17.1 per year, respectively.
after adjusting for potential conferencing factors, the subjects with TG high and very high were all due to death compared to normal TG subjects (risk ratio of 1.49 (95% confidence) The interval (CI) is 1.36-1.63, the P-lt;0.001 and the HR-3.08 (95% CI is 1.46-6. 50', P-lt;0.01) and ASCVD events (HR=1.61 (95% CI is 1.43-1.82), P&1.82 The risk of lt;0.001 and HR=2.30 (95% CI is 1.02-5.18) and P.lt;0.05) increases significantly.
, it can be seen that in a large number of patients with low to moderate cardiovascular risk, the moderate to severe increase in TG is associated with a significant increase in the risk of all-cause death and ASCVD events.
.